Main

Fields of interest:

• Cardiopulmonary diseases
• Bronchial asthma
• Aspirin-induced asthma
• Chemical mediators in diseases of circulatory and respiratory systems with special reference to eicosanoids
• Myocardial infarction
• Thrombinogenesis

Recent publications:

L. Mastalerz, M. Sanak, A. Gawlewicz, A. Gielicz, J. Faber, A. Szczeklik:
Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria.
J. Allergy. Clin. Immunol., Vol. 118(4), 2006, pp. 957-958.

A. Szczeklik, M. Sanak:
The broken balance in aspirin hypersensitivity.
Eur. J. Pharmacol., Vol. 8;533(1-3), 2006, pp. 145-155.

A. Szczeklik, J. Musial, A. Undas, M. Sanak:
Aspirin resistance.
J. Thromb. Haemost., Vol. 3(8), 2005, pp. 1655-1662.

A. Szczeklik, M. Sanak, E. Nizankowska-Mogilnicka, B. Kielbasa:
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
Curr. Opin. Pulm. Med., Vol. 10(1), 2004, pp. 51-56.

A. Szczeklik, D.D. Stevenson:
Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.
J. Allergy Clin. Immunol., Vol. 111(5), 2003, pp. 913-921.

A. Szczeklik, J. Musial, A. Undas:
Reasons for resistance to aspirin in cardiovascular disease.
Circulation, Vol. 106(22), 2002, e181-182.

A. Szczeklik, L. Mastalerz, E. Nizankowska, M. Sanak:
Montelukast for persistent asthma.
Lancet, Vol. 358(9291), 2001, pp. 1456-1457.

B. Dahlen, A. Szczeklik, J.J. Murray:
Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group.
N. Eng. J. Med., Vol. 344(2), 2001, p. 142.

A. Szczeklik, M. Sanak, A. Undas:
Platelet glycoprotein IIIa pl(a) polymorphism and effects of aspirin on thrombin generation.
Circulation, Vol. 103(6), 2001, E33-34.